Azanta A/S Completes DKK 46.4 million Capital Increase


Hellerup, Denmark, October 2, 2015.

Today Azanta A/S announce the successful completion of a DKK 46.4 million (Euro 6.22 million) equity capital increase. European Equity Partners (EEP), an investment company with focus on Life Sciences, led the capital increase, which included current shareholders and new shareholders. For more information on EEP please refer to:

Azanta’s Chairman of the Board, Lars Aaen, said “The Board of Directors have worked for some time to find an anchor investor for Azanta which could provide sufficient new equity capital to the Company as well as industry insight and strategic advice as a value added shareholder. The Company needed new capital in order service its financial obligations and to continue the development of its pipeline. With the arrival of EEP as a new shareholder, I am confident that we have found the best solution for the Company and its shareholders”.

David Kauffmann, Managing Partner at EEP, commented, “We think that Azanta is a company with an interesting potential. The Azanta management team, and associated drug development experts, have great industry and technical experience and we are excited of the prospects of working with the Company. Now that the Company is properly funded, the Azanta marketed product portfolio and in particular drug product pipeline, offers substantial opportunity, for growing Azanta into a successful specialty pharma company providing medical solutions for patients”.


About Azanta A/S
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. Azanta seeks to be an international market leader within certain specialty pharma product categories, employing innovative repositioning and drug formulation strategies. Azanta A/S currently markets (or makes available under special authorization) a portfolio of specialty pharmaceutical products, including Nimoral™, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta® for labour induction.

For further information, please visit

Contact Azanta:
Hanne Damgaard Jensen – CEO
Tel: + 45 – 70 25 95 45
Fax: + 45 – 70 25 95 46

For further interest in Azanta’s specialty pharma products or investigational cancer products, please contact your local representative or Azanta’s head office.

Find representative